DOTAGRAF gadoteric acid 5.59 g/20 mL solution for injection vial Australia - engleză - Department of Health (Therapeutic Goods Administration)

dotagraf gadoteric acid 5.59 g/20 ml solution for injection vial

bayer australia ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; tetraxetan; water for injections - dotagraf is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see section 5.1 pharmacodynamic properties ? clinical trials).

BACTHECAL baclofen 10 mg/5 mL intrathecal solution for injection ampoule Australia - engleză - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 10 mg/5 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

BACTHECAL baclofen 10 mg/20 mL intrathecal solution for injection ampoule Australia - engleză - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 10 mg/20 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

BACTHECAL baclofen 0.05 mg/1 mL intrathecal solution for injection ampoule Australia - engleză - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 0.05 mg/1 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 0.05 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

TRAMADOL AN tramadol hydrochloride 100 mg/2 mL solution for injection ampoule Australia - engleză - Department of Health (Therapeutic Goods Administration)

tramadol an tramadol hydrochloride 100 mg/2 ml solution for injection ampoule

juno pharmaceuticals pty ltd - tramadol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: sodium acetate trihydrate; water for injections - tramadol an solution for injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 200mg/100mL solution for injection infusion bag Australia - engleză - Department of Health (Therapeutic Goods Administration)

ropivacaine sandoz ropivacaine hydrochloride (as monohydrate) 200mg/100ml solution for injection infusion bag

sandoz pty ltd - ropivacaine hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sodium chloride - surgical anaesthesia (adults and children over 12 years of age). - epidural block for surgery including caesarean section. - intrathecal anaesthesia. - field block (minor nerve block and infiltration). - major nerve block. analgesia (adults and children over 12 years of age). - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). - continuous peripheral nerve block infusion or intermittent injections for post operative pain management. analgesia (children aged 0 - 12 years). - caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years . - continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years. - peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections support the use for up to 48 hours only).

ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 100mg/20mL solution for injection ampoule Australia - engleză - Department of Health (Therapeutic Goods Administration)

ropivacaine sandoz ropivacaine hydrochloride (as monohydrate) 100mg/20ml solution for injection ampoule

sandoz pty ltd - ropivacaine hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - surgical anaesthesia (adults and children over 12 years of age). - epidural block for surgery including caesarean section. - intrathecal anaesthesia. - field block (minor nerve block and infiltration). - major nerve block. analgesia (adults and children over 12 years of age). - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). - continuous peripheral nerve block infusion or intermittent injections for post operative pain management. analgesia (children aged 0 - 12 years). - caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years . - continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years. - peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections support the use for up to 48 hours only).

ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 50mg/10mL solution for injection ampoule Australia - engleză - Department of Health (Therapeutic Goods Administration)

ropivacaine sandoz ropivacaine hydrochloride (as monohydrate) 50mg/10ml solution for injection ampoule

sandoz pty ltd - ropivacaine hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age). - epidural block for surgery including caesarean section. - intrathecal anaesthesia. - field block (minor nerve block and infiltration). - major nerve block. analgesia (adults and children over 12 years of age). - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). - continuous peripheral nerve block infusion or intermittent injections for post operative pain management. analgesia (children aged 0 - 12 years). - caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years . - continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years. - peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections support the use for up to 48 hours only).

VARIVAX REFRIGERATED varicella virus vaccine live powder for  injection vial with prefilled diluent syringe Australia - engleză - Department of Health (Therapeutic Goods Administration)

varivax refrigerated varicella virus vaccine live powder for injection vial with prefilled diluent syringe

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - injection, powder for - excipient ingredients: monobasic potassium phosphate; potassium chloride; hydrolysed gelatin; sodium chloride; dibasic sodium phosphate; urea; sucrose; monosodium glutamate monohydrate - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

TRAMADOL SANDOZ tramadol hydrochloride 100 mg/2 mL injection ampoule Australia - engleză - Department of Health (Therapeutic Goods Administration)

tramadol sandoz tramadol hydrochloride 100 mg/2 ml injection ampoule

sandoz pty ltd - tramadol hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium acetate; water for injections - tramadol sandoz injections are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.